178 related articles for article (PubMed ID: 22381898)
21. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Murphy JD; Adusumilli S; Griffith KA; Ray ME; Zalupski MM; Lawrence TS; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):801-8. PubMed ID: 17379445
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma.
Cattaneo GM; Passoni P; Longobardi B; Slim N; Reni M; Cereda S; di Muzio N; Calandrino R
Radiother Oncol; 2013 Jul; 108(1):66-71. PubMed ID: 23726116
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Wang BH; Cao WM; Yu J; Wang XL
Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.
Goto Y; Nakamura A; Ashida R; Sakanaka K; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Isoda H; Masui T; Kodama Y; Takaori K; Hiraoka M; Mizowaki T
Radiat Oncol; 2018 Jun; 13(1):118. PubMed ID: 29940984
[TBL] [Abstract][Full Text] [Related]
27. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
28. Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy.
Nakamura A; Shibuya K; Nakamura M; Matsuo Y; Shiinoki T; Nakata M; Mizowaki T; Hiraoka M
Med Phys; 2013 Feb; 40(2):021701. PubMed ID: 23387724
[TBL] [Abstract][Full Text] [Related]
29. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
Terashima K; Demizu Y; Hashimoto N; Jin D; Mima M; Fujii O; Niwa Y; Takatori K; Kitajima N; Sirakawa S; Yonson K; Hishikawa Y; Abe M; Sasaki R; Sugimura K; Murakami M
Radiother Oncol; 2012 Apr; 103(1):25-31. PubMed ID: 22300608
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
[TBL] [Abstract][Full Text] [Related]
33. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer.
Isohashi F; Yoshioka Y; Mabuchi S; Konishi K; Koizumi M; Takahashi Y; Ogata T; Maruoka S; Kimura T; Ogawa K
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):728-34. PubMed ID: 22727885
[TBL] [Abstract][Full Text] [Related]
34. Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?
Xu B; Guo Y; Chen Y; Lu H; Tang T; Yue Z; Guan G; Chi P; Lin C
Radiat Oncol; 2015 Dec; 10():257. PubMed ID: 26684643
[TBL] [Abstract][Full Text] [Related]
35. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
Milano MT; Chmura SJ; Garofalo MC; Rash C; Roeske JC; Connell PP; Kwon OH; Jani AB; Heimann R
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):445-53. PubMed ID: 15145161
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Bjerregaard JK; Mortensen MB; Jensen HA; Nielsen M; Pfeiffer P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):909-15. PubMed ID: 22172900
[TBL] [Abstract][Full Text] [Related]
37. Interfractional dose variations in intensity-modulated radiotherapy with breath-hold for pancreatic cancer.
Nakamura M; Shibuya K; Nakamura A; Shiinoki T; Matsuo Y; Nakata M; Sawada A; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1619-26. PubMed ID: 21477941
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Huang J; Robertson JM; Margolis J; Balaraman S; Gustafson G; Khilanani P; Nadeau L; Jury R; McIntosh B
Radiother Oncol; 2011 May; 99(2):114-9. PubMed ID: 21621866
[TBL] [Abstract][Full Text] [Related]
39. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies.
Bae SH; Kim MS; Cho CK; Kang JK; Lee SY; Lee KN; Lee DH; Han CJ; Yang KY; Kim SB
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e469-74. PubMed ID: 23078899
[TBL] [Abstract][Full Text] [Related]
40. Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer.
Nagar H; Boothe D; Parikh A; Yondorf M; Parashar B; Gupta D; Holcomb K; Caputo T; Chao KS; Nori D; Wernicke AG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):665-9. PubMed ID: 24138915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
